Novel treatments, such as FOXM1 inhibitor co-treatment with platinum, are potential therapeutic strategies to reduce the necessary dosage of cisplatin and enhance the therapeutic efficacy in treating ovarian cancer. This evidence concerns the gene FOXM1 and ovarian cancer.